Autism Spectrum Disorder (ASD) includes a group of neurodevelopmental disorders characterized by core symptoms such as impaired social interaction and communication, repetitive and stereotyped behaviors, and restricted interests. To date, there are no effective treatments for these core symptoms. Several studies have shown that the brain serotonin (5-HT) neurotransmission system is altered in both ASD patients and animal models of the disease. Multiple pieces of evidence suggest that targeting 5-HT receptors may treat the core symptoms of ASD and associated intellectual disabilities. In fact, stimulation of the 5-HT_1A receptor reduces repetitive and restricted behaviors, blockade of the 5-HT_2A receptor reduces both learning deficits and repetitive behavior, and activation of the 5-HT₇ receptor improves cognitive performances and reduces repetitive behavior. On such a basis, a set of novel arylpiperazine derivatives have been synthesized by pursuing unprecedently reported activity profiles: dual 5-HT_1A/5-HT₇ receptor agonist properties and mixed 5-HT_1A agonist/5-HT₇ agonist/5-HT_2A antagonist properties. Dual 5-HT_1AR/5-HT₇R agonists and the mixed 5-HT_1AR agonist/5-HT₇R agonist/5-HT_2AR antagonists have been identified. These compounds are metabolically stable in vitro and have suitable central nervous system drug-like properties.